Celebrating Native American Heritage Month: Meet Dr. Kent Kwoh, A Champion for Health Equity
November 14, 2024
During Native American Heritage Month, we celebrate a dedicated champion of health equity. As Chief of Rheumatology and...
Baricitinib Development as a Lupus Treatment Discontinued
Baricitinib Development as a Lupus Treatment Discontinued
January 28, 2022
The Lupus Research Alliance is disappointed that the Phase 3 development program of OLUMIANT® (baricitinib) as a potential treatment for adults with systemic lupus erythematosus (SLE) has been discontinued.
The drug’s manufacturer Lilly made this decision based on results from two Phase 3 trials (SLE-BRAVE-I and II). While SLE-BRAVE-I showed a significant reduction in lupus disease activity as evaluated by the SRI-4 standard measurement tool, the SLE-BRAVE-II trial did not. It’s important to note that safety was consistent with previous data on the drug and was not a factor in the decision to discontinue the development program.
The LRA looks forward to seeing further analysis of the data in progress from Lilly to help the scientific community better understand the disease.
Click here for announcement from Lilly.
